PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Matthew J. Ellis|Molecular Cancer Therapeutics|2024Cited by 20
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Eric C. Chang, Anran Chen et al.|Cancer Research Communications|2023Cited by 8
Table S1 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0
Table S3 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0
Figure S5 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0